Letters
Journal of Medicinal Chemistry, 2005, Vol. 48, No. 23 7095
(11) Toide, K.; Iwamoto, Y.; Fujiwara, T.; Abe, H. JTP-4819: a novel
prolyl endopeptidase inhibitor with potential as a cognitive
enhancer. J. Pharmacol. Exp. Ther. 1995, 274, 1370-1378.
(12) Toide, K.; Shinoda, M.; Fujiwara, T.; Iwamoto, Y. Effect of a novel
prolyl endopeptidase inhibitor, JTP-4819, on spatial memory and
central cholinergic neurons in aged rats. Pharmacol. Biochem.
Behav. 1997, 56, 427-434.
(13) Schneider, J. S.; Giardiniere, M.; Morain, P. Effects of the prolyl
endopeptidase inhibitor S 17092 on cognitive deficits in chronic
low dose MPTP-treated monkeys. Neuropsychopharmacology
2002, 26, 176-182.
(14) Schulz, I.; Gerhartz, B.; Neubauer, A.; Holloschi, A.; Heiser, U.;
Hafner, M.; Demuth, H.-U. Modulation of inositol 1,4,5-triph-
osphate concentration by prolyl endopeptidase inhibition. Eur.
J. Biochem. 2002, 269, 5813-5820.
(15) Williams, R. S.; Eames, M.; Ryves, W. J.; Viggars, J.; Harwood,
A. J. Loss of a prolyl oligopeptidase confers resistance to lithium
by elevation of inositol (1,4,5) trisphosphate. EMBO J. 1999, 18,
2734-2745.
(16) Williams, R. S.; Cheng, L.; Mudge, A. W.; Harwood, A. J. A
common mechanism of action for three mood-stabilizing drugs.
Nature 2002, 417, 292-295.
(17) Hausch, F.; Shan, L.; Santiago, N. A.; Gray, G. M.; Khosla, C.
Intestinal digestive resistance of immunodominant gliadin pep-
tides. Am. J. Physiol.: Gastrointest. Liver. Physiol. 2002, 283,
G996-G1003.
(18) Shan, L.; Marti, T.; Sollid, L. M.; Gray, G. M.; Khosla, C.
Comparative biochemical analysis of three bacterial prolyl
endopeptidases: implications for coeliac sprue. Biochem. J. 2004,
383, 311-318.
(19) Shan, L.; Molberg, O.; Parrot, I.; Hausch, F.; Filiz, F.; Gray, G.
M.; Sollid, L. M.; Khosla, C. Structural basis for gluten intoler-
ance in celiac sprue. Science 2002, 297, 2275-2279.
(20) Santana, J. M.; Grellier, P.; Schrevel, J.; Teixeira, A. R. A
Trypanosoma cruzi-secreted 80 kDa proteinase with specificity
for human collagen types I and IV. Biochem. J. 1997, 325 (Part
1), 129-137.
(21) Grellier, P.; Vendeville, S.; Joyeau, R.; Bastos, I. M.; Drobecq,
H.; Frappier, F.; Teixeira, A. R.; Schrevel, J.; Davioud-Charvet,
E.; Sergheraert, C.; Santana, J. M. Trypanosoma cruzi prolyl
oligopeptidase Tc80 is involved in nonphagocytic mammalian
cell invasion by trypomastigotes. J. Biol. Chem. 2001, 276,
47078-47086.
(22) Kato, T.; Nakano, T.; Kojima, K.; Nagatsu, T.; Sakakibara, S.
Changes in prolyl endopeptidase during maturation of rat brain
and hydrolysis of substance P by the purified enzyme. J.
Neurochem. 1980, 35, 527-535.
(23) Yoshimoto, T.; Ogita, K.; Walter, R.; Koida, M.; Tsuru, D. Post-
proline cleaving enzyme. Synthesis of a new fluorogenic sub-
strate and distribution of the endopeptidase in rat tissues and
body fluids of man. Biochim. Biophys. Acta 1979, 569, 184-192.
(24) Wolbers, F.; Buijtenhuijs, P.; Haanen, C.; Vermes, I. Apoptotic
cell death kinetics in vitro depend on the cell types and the
inducers used. Apoptosis 2004, 9, 385-392.
(25) Vena¨la¨inen, J. I.; Juvonen, R. O.; Forsberg, M. M.; Garcia-
Horsman, A.; Poso, A.; Walle´n, E. A. A.; Gynther, J.; Ma¨nnisto¨,
P. T. Substrate-dependent, non-hyperbolic kinetics of pig brain
prolyl oligopeptidase and its tight binding inhibition by JTP-
4819. Biochem. Pharmacol. 2002, 64, 463-471.
(26) Jarho, E. M.; Walle´n, E. A.; Christiaans, J. A.; Forsberg, M. M.;
Vena¨la¨inen, J. I.; Ma¨nnisto¨, P. T.; Gynther, J.; Poso, A. Dicar-
boxylic acid azacycle l-prolyl-pyrrolidine amides as prolyl oli-
gopeptidase inhibitors and three-dimensional quantitative struc-
ture-activity relationship of the enzyme-inhibitor interactions.
J. Med. Chem. 2005, 48, 4772-4782.
(27) Walle´n, E. A. A.; Christiaans, J. A. M.; Saario, S. M.; Forsberg,
M. M.; Vena¨la¨inen, J. I.; Paso, H. M.; Ma¨nnisto¨, P. T.; Gynther,
J. 4-Phenylbutanoyl-2(S)-acylpyrrolidines and 4-phenylbutanoyl-
L-prolyl-2(S)-acylpyrrolidines as prolyl oligopeptidase inhibitors.
Bioorg. Med. Chem. 2002, 10, 2199-2206.
Figure 3. Dissociation of 2 from the active site of POP. A
mixture of 10 nM inhibitor and 5 nM purified porcine POP
was incubated for 30 min at 23 °C. Then, Z-L-Pro-L-prolinal
was added to give 1 µM. Samples of 1 mL were taken at
appropriate times, filtered, and washed once. The concentrate
was dissolved in the assay buffer, and the fluorescence
intensity was measured with a Victor2 fluorescence plate
reader at 485 nm (excitation) and 535 nm (emission). Each
data point represents the mean ( SEM of two to three
independent measurements.
fluorescent probe. This compound is a new fluorescent
scientific tool that is likely to have many applications
in the expanding field of POP research.
Acknowledgment. We thank Tiina Koivunen and
Jaana Leskinen for their excellent technical assistance
and Ministry of Education of Finland for financial
support (to J.I.V.)
Supporting Information Available: Experimental de-
tails and analytical data. This material is available free of
References
(1) Rennex, D.; Hemmings, B. A.; Hofsteenge, J.; Stone, S. R. cDNA
cloning of porcine brain prolyl endopeptidase and identification
of the active-site seryl residue. Biochemistry 1991, 30, 2195-
2203.
(2) Vena¨la¨inen, J. I.; Juvonen, R. O.; Ma¨nnisto¨, P. T. Evolutionary
relationships of the prolyl oligopeptidase family enzymes. Eur.
J. Biochem. 2004, 271, 2705-2715.
(3) Cunningham, D. F.; O’Connor, B. Proline specific peptidases.
Biochim. Biophys. Acta 1997, 1343, 160-186.
(4) Belleme`re, G.; Morain, P.; Vaudry, H.; Je´gou, S. Effect of S
17092, a novel prolyl endopeptidase inhibitor, on substance P
and alpha-melanocyte-stimulating hormone breakdown in the
rat brain. J. Neurochem. 2003, 84, 919-929.
(5) Belleme`re, G.; Vaudry, H.; Morain, P.; Jegou, S. Effect of prolyl
endopeptidase inhibition on arginine-vasopressin and thyrotro-
phin-releasing hormone catabolism in the rat brain. J. Neuroen-
docrinol. 2005, 17, 306-313.
(6) Toide, K.; Fujiwara, T.; Iwamoto, Y.; Shinoda, M.; Okamiya, K.;
Kato, T. Effect of a novel prolyl endopeptidase inhibitor, JTP-
4819, on neuropeptide metabolism in the rat brain. Naunyn-
Schmiedeberg’s Arch. Pharmacol. 1996, 353, 355-362.
(7) de Wied, D.; Gaffori, O.; van Ree, J. M.; de Jong, W. Central
target for the behavioural effects of vasopressin neuropeptides.
Nature 1984, 308, 276-278.
(8) Haseno¨hrl, R. U.; Souza-Silva, M. A.; Nikolaus, S.; Tomaz, C.;
Brandao, M. L.; Schwarting, R. K.; Huston, J. P. Substance P
and its role in neural mechanisms governing learning, anxiety
and functional recovery. Neuropeptides 2000, 34, 272-280.
(9) Kovacs, G. L.; De Wied, D. Peptidergic modulation of learning
and memory processes. Pharmacol. Rev. 1994, 46, 269-291.
(10) Atack, J. R.; Suman-Chauhan, N.; Dawson, G.; Kulagowski, J.
J. In vitro and in vivo inhibition of prolyl endopeptidase. Eur.
J. Pharmacol. 1991, 205, 157-163.
JM0509187